Slider
News & Media
  • 2nd USFDA Inspection of Formulation facility successfully completed with Zero 483’s in February 2018
  • Expansion of Oncology block to meet growing market demand
  • WHO-GMP Inspection of Formulation facility successfully completed in November 2017
  • 5th USFDA Inspection of API facility successfully completed with Zero 483 observations in November 2017
  • 3rd EUGMP inspection of API facility successfully completed in September 2017
  • 1st USFDA Inspection of the Formulation facility successfully completed in July 2017
  • Concord participated in various National and international conferences of medical fraternity in the promoted segment of Nephrology & organ transplantation in India as well as Industrial exhibition globally.
  • CRAM projects initiated with a Global Biopharmaceutical Company in the area of Natural Products.
  • Launched Domestic Business Operation into super specialty segments like Immunology, Organ Transplantation & Chronic Kidney Disease segment by forming a business unit “INTRA”
  • Concord Biotech signs MoU with Gujarat Government at Vibrant Gujarat Summit 2017
DSC_7724_300x200
DSC_7620_300
DSC_7822r
News Media_4